Loading stock data…
ILMN
$135.78+9.04 (+7.13%)
Market ClosedLast close May 1
Illumina, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Illumina, Inc. in the Healthcare sector is trading at $135.78. The stock is currently 13% below its 52-week high of $155.53, remaining 15.0% above its 200-day moving average. Technical signals show neutral RSI of 60 and bearish MACD signal, explaining why ILMN maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$135.78
Potential Upside
13.7%
Whystock Fair Value$154.42
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Buy
Mean target$138.94+2.3%
Range$95.00 – $175.00
Fundamentals
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$19.95B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.94
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.49
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
46.16%
Volume
Today's trading volume
2.77M
Recent News
ILMN Stock Up on Q1 Earnings & Revenue Beat, Margins Expand, '26 View Up
Illumina stock jumps after Q1 earnings and revenue beat, with margin expansion and raised 2026 outlook signaling continued growth momentum.
Illumina Inc (ILMN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ...
Illumina Inc (ILMN) reports robust Q1 performance with increased revenue and EPS, while raising 2026 guidance amid strong clinical market demand.
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Illumina Q1 Earnings Call Highlights
Illumina (NASDAQ:ILMN) reported first-quarter 2026 results that came in above its guidance range on revenue, margins, and earnings per share, supported by strength in clinical demand and better-than-expected NovaSeq X instrument placements. Chief Executive Officer Jacob Thaysen said the company was
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of +9.70% and +1.15%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?